UK’s NICE Dismisses Drug Delay Statements

The UK’s National Institute for Health and Clinical Excellence (NICE) has not been requested to alter the basis of their assessments “simply to save money,” NICE’s chief executive, Sir Andrew Dillon, has stated. Sir Andrew Dillon was replying to media reports from earlier this week, which claimed that the UK government is deferring the introduction

Continue Reading

Only Medics at the 2012 BrAPP Annual Symposium

Only Medics will be attending this year’s BrAPP Conference on 1st March 2012 in London. 2012 sees BrAPP celebrating its 55th year as the professional association for pharmaceutical physicians. The conference starts at 9am, and is followed by a three course dinner with guest speaker, Professor Trevor Jones CBE. The conference offers attendees the chance

Continue Reading

Berkeley Lab Discover New Evidence On How ‘Good’ Cholesterol Turns ‘Bad’

Researchers with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered new proof to clarify how cholesteryl ester transfer protein (CETP) mediates the move of cholesterol from “good” high density lipoproteins (HDLs) to “bad” low density lipoproteins (LDLs). The outcomes of the research study were conveyed in the journal Nature Chemical

Continue Reading

US green light for Merck & Co’s eye drug Zioptan

The US Food and Drug Administration has given the nod to Merck & Co’s eye solution Zioptan for lowering intraocular pressure in patients with certain eye conditions. Shares in the drugmaker were given a bump after it announced that Zioptan (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution, has been approved for

Continue Reading